What does the evidence say about Resveratrol Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Resveratrol Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Observational associations between dietary patterns and reduced dementia risk have prompted investigations of dietary bioactives (DBs) as cognitive nutraceuticals. [Kumari A (2026); evidence level 2] - Findings are synthesized qualitatively; no formal meta-analysis or risk of bias assessment was conducted. [Kumari A (2026); evidence level 2] - Cannabinoids improved behavioral symptoms but showed no measurable cognitive effects. [Kumari A (2026); evidence level 2] - Methods: This critical narrative review examines interventional trials for nine prominent DBs relevant to AD: docosahexaenoic acid (DHA), curcumin, resveratrol, epigallocatechin gallate (EGCG), nicotinamide riboside (NR), tricaprilin, vitamin E (α-tocopherol), cannabinoids, and NIC5-15 (D-pinitol). [Kumari A (2026); evidence level 2] - Dietary patterns have emerged as modifiable risk factors that may influence disease onset and progression. [Fekete M (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.